VIVUS (NASDAQ:VVUS) Stock Rating Lowered by ValuEngine

ValuEngine downgraded shares of VIVUS (NASDAQ:VVUS) from a sell rating to a strong sell rating in a research report sent to investors on Friday, December 1st.

VIVUS (NASDAQ VVUS) traded down $0.02 during trading hours on Friday, reaching $0.59. 1,592,203 shares of the company’s stock traded hands, compared to its average volume of 488,457. The stock has a market cap of $62.54, a P/E ratio of 1.74 and a beta of 0.77. The company has a debt-to-equity ratio of 643.86, a quick ratio of 7.09 and a current ratio of 7.47. VIVUS has a 12 month low of $0.57 and a 12 month high of $1.46.

VIVUS (NASDAQ:VVUS) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.07. The business had revenue of $15.19 million for the quarter, compared to the consensus estimate of $16.00 million. VIVUS had a net margin of 26.71% and a return on equity of 344.23%. The business’s revenue for the quarter was up 13.8% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.09) EPS. research analysts anticipate that VIVUS will post -0.32 earnings per share for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in VVUS. Bank of New York Mellon Corp boosted its holdings in shares of VIVUS by 3.6% in the 1st quarter. Bank of New York Mellon Corp now owns 106,842 shares of the biopharmaceutical company’s stock valued at $120,000 after acquiring an additional 3,694 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of VIVUS by 84.8% in the 2nd quarter. Russell Investments Group Ltd. now owns 148,600 shares of the biopharmaceutical company’s stock valued at $180,000 after acquiring an additional 68,200 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in shares of VIVUS by 70.9% in the 2nd quarter. Acadian Asset Management LLC now owns 1,837,822 shares of the biopharmaceutical company’s stock valued at $2,241,000 after acquiring an additional 762,392 shares during the last quarter. Spark Investment Management LLC purchased a new stake in shares of VIVUS in the 2nd quarter valued at $100,000. Finally, AJO LP purchased a new stake in shares of VIVUS in the 2nd quarter valued at $3,329,000. 31.35% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This story was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://ledgergazette.com/2017/12/11/vivus-vvus-rating-lowered-to-strong-sell-at-valuengine.html.

About VIVUS

VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for VIVUS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply